Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Detection of ECG effects of (2R,4R)-monatin, a sweet flavored isomer of a component first identified in the root bark of the Sclerochitin ilicifolius plant.

Darpo B, Bjornsson TD, Brathwaite WA, Crincoli CM, Eapen AK, Fisher GL, Kowey PR, Miller MP, Nikiforov AI, Rihner MO, Zhou M.

Food Chem Toxicol. 2016 May;91:217-24. doi: 10.1016/j.fct.2015.12.023. Epub 2015 Dec 31.

PMID:
26747976
2.

Pharmacometrics and the transition to model-based development.

Grasela TH, Dement CW, Kolterman OG, Fineman MS, Grasela DM, Honig P, Antal EJ, Bjornsson TD, Loh E.

Clin Pharmacol Ther. 2007 Aug;82(2):137-42. Review.

PMID:
17632539
3.

A review and assessment of potential sources of ethnic differences in drug responsiveness.

Bjornsson TD, Wagner JA, Donahue SR, Harper D, Karim A, Khouri MS, Murphy WR, Roman K, Schneck D, Sonnichsen DS, Stalker DJ, Wise SD, Dombey S, Loew C.

J Clin Pharmacol. 2003 Sep;43(9):943-67. Review.

PMID:
12971027
4.

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER).

Drug Metab Dispos. 2003 Jul;31(7):815-32.

PMID:
12814957
5.

The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups.

J Clin Pharmacol. 2003 May;43(5):443-69. Review.

PMID:
12751267
6.

Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers.

Greenberg HE, Wissel P, Barrett J, Barchowsky A, Gould R, Farrell D, Panebianco D, Hand E, Gillen L, Goldberg MR, Bjornsson TD.

J Clin Pharmacol. 2000 May;40(5):496-507.

PMID:
10806603
7.

Immunohistochemical demonstration of tissue transglutaminase in amyloid plaques.

Zhang W, Johnson BR, Suri DE, Martinez J, Bjornsson TD.

Acta Neuropathol. 1998 Oct;96(4):395-400.

PMID:
9797004
8.

Effect of food on the absorption of eptastigmine.

Bjornsson TD, Troetel WM, Imbimbo BP.

Eur J Clin Pharmacol. 1998 May;54(3):243-7.

PMID:
9681667
9.

Time of peak drug concentration after a single dose and a dose at steady state.

Greenberg HE, England MJ, Hellriegel ET, Bjornsson TD.

J Clin Pharmacol. 1997 Jun;37(6):480-5.

PMID:
9208354
10.
11.
12.

Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies.

Hellriegel ET, Bjornsson TD, Hauck WW.

Clin Pharmacol Ther. 1996 Dec;60(6):601-7. No abstract available.

PMID:
8988062
13.

A classification of drug action based on therapeutic effects.

Bjornsson TD.

J Clin Pharmacol. 1996 Aug;36(8):669-73. Review.

PMID:
8877669
14.

Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers.

Waldman SA, Vitow C, Osborne B, Gillen L, Argentieri DC, Wong FA, Smith IL, Chow AT, Misiti J, Bjornsson TD.

J Clin Pharmacol. 1996 May;36(5):462-8.

PMID:
8739025
15.

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.

Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD.

Clin Pharmacol Ther. 1995 Dec;58(6):641-9.

PMID:
8529329
16.

Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin.

Kong AN, Tomasko L, Waldman SA, Osborne B, Deutsch PJ, Goldberg MR, Bjornsson TD.

J Clin Pharmacol. 1995 Oct;35(10):1008-15.

PMID:
8568008
17.

The regulation of plasminogen activators and plasminogen activator inhibitor type 1 in endothelial cells by sex hormones.

Sobel MI, Winkel CA, Macy LB, Liao P, Bjornsson TD.

Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):801-8.

PMID:
7573247
18.

Novel oral medication delivery system for famotidine.

Schwartz JI, Yeh KC, Berger ML, Tomasko L, Hoover ME, Ebel DL, Stauffer LA, Han R, Bjornsson TD.

J Clin Pharmacol. 1995 Apr;35(4):362-7.

PMID:
7650224
19.

Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.

Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al.

Hypertension. 1995 Jan;25(1):37-46.

PMID:
7843751
20.
21.

Expression of intravenous-infusion equations in terms of coefficients and exponents of bolus intravenous equations.

Liu NL, Bjornsson TD.

J Pharm Sci. 1994 Feb;83(2):267-8. No abstract available.

PMID:
8169803
22.

Oral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast.

Schwartz JI, Margolskee DJ, Bjornsson TD, Williams VC, Hsieh JY, Lin CC, Rogers JD.

Br J Clin Pharmacol. 1993 Nov;36(5):464-6.

23.

Lovastatin does not affect oral glucose tolerance in hypercholesterolemic patients.

McCrea JB, Fruncillo RJ, Holland SD, Conroy JA, Shingo S, Spector R, Bjornsson TD.

J Clin Pharmacol. 1993 Jun;33(6):581-5.

PMID:
8366184
24.

Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.

Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD.

Hypertension. 1993 May;21(5):704-13.

PMID:
8491505
25.
27.

Molecular cloning of the alcohol/hydroxysteroid form (hSTa) of sulfotransferase from human liver.

Kong AN, Yang L, Ma M, Tao D, Bjornsson TD.

Biochem Biophys Res Commun. 1992 Aug 31;187(1):448-54.

PMID:
1520333
29.

Fibrinolytic activity after vessel wall injury.

Shi Y, Nardone D, Hernandez-Martinez A, Walinsky P, Bjornsson TD, Zalewski A.

J Am Coll Cardiol. 1992 Feb;19(2):441-3.

30.
31.

Acidic fibroblast growth factor promotes vascular repair.

Bjornsson TD, Dryjski M, Tluczek J, Mennie R, Ronan J, Mellin TN, Thomas KA.

Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8651-5.

32.

Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates.

Zalewski A, Shi Y, Nardone D, Bravette B, Weinstock P, Fischman D, Wilson P, Goldberg S, Levin DC, Bjornsson TD.

Circulation. 1991 May;83(5):1685-91.

PMID:
1902406
33.
34.

Norfloxacin does not alter warfarin's disposition or anticoagulant effect.

Rocci ML Jr, Vlasses PH, Distlerath LM, Gregg MH, Wheeler SC, Zing W, Bjornsson TD.

J Clin Pharmacol. 1990 Aug;30(8):728-32.

PMID:
2401751
35.

Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men.

Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH.

Clin Pharmacol Ther. 1990 May;47(5):557-64.

PMID:
2188770
36.

Clinical evaluation of a benzofuroquinolizine alpha 2-adrenoceptor antagonist.

Gertz BJ, Vlasses PH, Rocci ML Jr, Coker LD, Williams V, Bjornsson TD, Jones KH.

Clin Pharmacol Ther. 1989 Nov;46(5):566-75.

PMID:
2573444
37.

Bovine aortic endothelial cell transglutaminase. Enzyme characterization and regulation of activity.

Korner G, Schneider DE, Purdon MA, Bjornsson TD.

Biochem J. 1989 Sep 1;262(2):633-41.

38.

Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.

Dryjski M, Schneider DE, Mojaverian P, Kuo BS, Bjornsson TD.

Br J Clin Pharmacol. 1989 Aug;28(2):188-92.

39.
40.
41.

Oral dipyridamole increases plasma adenosine levels in human beings.

German DC, Kredich NM, Bjornsson TD.

Clin Pharmacol Ther. 1989 Jan;45(1):80-4.

PMID:
2910640
42.

Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid.

Dryjski M, Mikat E, Bjornsson TD.

J Vasc Surg. 1988 Nov;8(5):623-33.

PMID:
2460647
43.
44.
45.

Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.

Bjornsson TD, Schneider DE, Hecht AR.

J Pharmacol Exp Ther. 1988 Jun;245(3):804-8.

PMID:
3164387
46.
47.

Effective antiplatelet drug concentrations in experimental arterial thromboembolism.

Bjornsson TD, Hanson SR, Harker LA.

Thromb Res. 1987 Nov 1;48(3):337-48.

PMID:
3433258
48.

Pharmacokinetics of streptokinase in patients based on amidolytic activator complex activity.

Grierson DS, Bjornsson TD.

Clin Pharmacol Ther. 1987 Mar;41(3):304-13.

PMID:
3816018
49.

Benzodiazepine pharmacodynamics: evidence for biophase rate limiting mechanisms.

Ellinwood EH Jr, Nikaido AM, Heatherly DG, Bjornsson TD.

Psychopharmacology (Berl). 1987;91(2):168-74.

PMID:
2883695
50.

Bimodal frequency distribution of rat hepatic vitamin K-dependent carboxylation rate.

Cocchetto DM, Bjornsson TD.

Life Sci. 1986 Nov 24;39(21):1977-83.

PMID:
3784766

Supplemental Content

Loading ...
Support Center